Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis

• Market Cap: ¥23.47B
• Dividend Yield: N/A
• Average Volume (3M): 526.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: -2.34%
• EPS Growth: -278.32%
• Country: JP
• Employees: 211
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 2.33
• Shares Outstanding: 40,610,200
• 10 Day Avg. Volume: 161,950
• 30 Day Avg. Volume: 526,650
• PEG Ratio: 1.02
• Price to Book (P/B): 3.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Japan Tissue Engineering Co., Ltd. scores moderately due to a strong balance sheet and technical momentum. However, profitability and cash flow concerns, alongside a negative P/E ratio, weigh on the overall assessment. The company's financial stability provides a foundation, but the lack of earnings growth and cash flow issues are key risks.

Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model

Company Description

Japan Tissue Engineering Co., Ltd. (J-TEC) is a pioneering company in the field of regenerative medicine, focused on the research, development, and commercialization of tissue-engineered medical products. The company operates primarily in the biotechnology sector, offering innovative solutions for tissue and organ regeneration. J-TEC's core products include autologous cultured epidermis, cartilage, and corneal epithelium, which are designed to aid in the repair and regeneration of damaged tissues and improve patient outcomes.

How the Company Makes Money

J-TEC generates revenue through the sale of its tissue-engineered products, which are used in medical treatments and procedures. The company's primary revenue streams come from the commercial sales of its cultured tissue products to hospitals and medical institutions. Additionally, J-TEC is involved in collaborative research and development projects with academic institutions and other corporations, which may provide additional funding and revenue opportunities. The company also invests in intellectual property development and may earn income through licensing agreements or partnerships with other entities in the regenerative medicine space.

Japan Tissue Engineering Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
2.44B	2.51B	2.03B	2.10B	2.26B	2.31B
	Gross Profit
1.49B	1.69B	1.14B	1.26B	1.16B	1.19B
	EBIT
-100.30M	144.51M	-728.12M	-498.18M	-466.86M	-235.18M
	EBITDA
12.67M	278.56M	-597.00M	-374.00M	-359.89M	-112.00M
	Net Income Common Stockholders
-153.61M	143.17M	-729.32M	-497.89M	-466.62M	-287.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.07B	4.27B	4.13B	4.93B	5.28B	5.75B
	Total Assets
6.45B	6.99B	6.88B	7.60B	8.12B	8.45B
	Total Debt
0.00	0.00	133.00K	936.00K	1.74M	3.05M
	Net Debt
-4.07B	-2.07B	-4.13B	-4.93B	-5.27B	-5.75B
	Total Liabilities
717.83M	908.43M	946.15M	931.66M	954.78M	820.54M
	Stockholders Equity
5.73B	6.08B	5.94B	6.67B	7.16B	7.63B
Cash Flow		Free Cash Flow
0.00	938.00K	-798.60M	-342.48M	-473.98M	-175.82M
	Operating Cash Flow
0.00	274.14M	-622.60M	-225.25M	-399.59M	-84.58M
	Investing Cash Flow
0.00	-242.23M	1.12B	-116.48M	125.89M	209.05M
	Financing Cash Flow
0.00	-134.00K	-803.00K	-823.00K	-1.30M	-3.19M

Japan Tissue Engineering Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 578.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Neutral. The current price of 578 is below the 20-day moving average (MA) of 607.80, above the 50-day MA of 511.44, and above the 200-day MA of 513.85, indicating a neutral trend. The MACD of 26.28 indicates Positive momentum. The RSI at 50.80 is Neutral, neither overbought nor oversold. The STOCH value of 5.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7774.

Japan Tissue Engineering Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4578	72 Outperform	$3.55T	10.16	13.46%	1.71%	14.52%	156.70%
4587	70 Outperform	$226.94B	15.28	29.98%	―	66.89%	506.88%
7774	58 Neutral	¥23.47B	―		―	-2.34%	-278.32%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
4974	51 Neutral	¥94.04B	90.34		2.18%	-9.69%	-103.31%
4593	49 Neutral	¥35.31B	―		―	374.19%	35.53%
4571	40 Underperform	¥8.90B	―	-26.97%	―	-30.46%	39.41%

Japan Tissue Engineering Co., Ltd. Corporate Events

Japan Tissue Engineering Co., Ltd. Reports Third Quarter Financial Results and Adjusted Forecast

Japan Tissue Engineering Co., Ltd. reported a decrease in net sales and net income for the third quarter of FY2024 compared to the previous year, reflecting ongoing financial challenges. The company has revised its forecasts for FY2024, indicating a cautious outlook amid a competitive market environment, which could have implications for its stakeholders and market position.